SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Hey, guys. Thanks for joining us. Pleasure to have the management team from SpringWorks join us. I know there's a lot of activity coming up in the coming months but let me turn it over to you first to kick things off.
Thanks, Umer. Obviously, we appreciate you hosting us today at your conference. It's a pleasure to be here to share updates on SpringWorks ahead of -- as you said, it will be a busy 12 months ahead of us with data across the portfolio and potentially a drug launch upcoming in 2023. Before going into specific questions, I'd love to start with a brief overview of SpringWorks.
For those who don't know us, we are a clinical-stage oncology company committed to making a profound impact on patients suffering from severe rare diseases and cancer. We're advancing a diversified pipeline spanning our three core focus areas, which are rare tumors, multiple myeloma through BCMA combinations, and biomarker-defined metastatic solid tumors.
Our late-stage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
